Cellectis Sa Stock Today
| CMVLF Stock | USD 1.25 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 13
|
Cellectis is trading at 1.25 as of the 31st of January 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 1.25. Cellectis has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 1st of January 2025 and ending today, the 31st of January 2025. Click here to learn more.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. The company has 55.59 M outstanding shares. More on Cellectis SA
Moving together with Cellectis Pink Sheet
| 0.83 | NVO | Novo Nordisk AS Earnings Call This Week | PairCorr |
| 0.82 | NONOF | Novo Nordisk AS Earnings Call This Week | PairCorr |
Moving against Cellectis Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cellectis Pink Sheet Highlights
| Chairman | Andre Choulika |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Cellectis SA [CMVLF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Small-Cap' category with a current market capitalization of 131.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cellectis's market, we take the total number of its shares issued and multiply it by Cellectis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cellectis SA classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 55.59 M outstanding shares.
Cellectis SA has accumulated about 153.13 M in cash with (104.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cellectis Probability Of Bankruptcy
Ownership AllocationCellectis holds a total of 55.59 Million outstanding shares. Almost 90.2 percent of Cellectis outstanding shares are held by general public with 9.8 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cellectis Ownership Details
Cellectis SA Risk Profiles
| Mean Deviation | 1.69 | |||
| Standard Deviation | 5.41 | |||
| Variance | 29.29 | |||
| Risk Adjusted Performance | (0.13) |
Cellectis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cellectis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stocks Directory Now
Stocks DirectoryFind actively traded stocks across global markets |
| All Next | Launch Module |
Cellectis Corporate Management
| MarieBleuenn Terrier | General Counsel, Member of the Executive Committee | Profile | |
| Dr MBA | Chief Officer | Profile | |
| Valerie Cros | Principal Officer | Profile | |
| Kyung NamWortman | Ex Officer | Profile | |
| Philippe Duchateau | Chief Scientific Officer | Profile |
Additional Information and Resources on Investing in Cellectis Pink Sheet
When determining whether Cellectis SA is a strong investment it is important to analyze Cellectis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cellectis' future performance. For an informed investment choice regarding Cellectis Pink Sheet, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectis SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.